Testing pembrolizumab plus ataluren for metastatic dMMR or pMMR cancer
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This early-phase trial tests pembrolizumab combined with ataluren for people with metastatic colorectal cancer that has either dMMR or pMMR, and for metastatic dMMR endometrial cancer. The goal is to see whether this combination can shrink tumors or improve outcomes for cancers with specific mismatch repair (MMR) features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer (pMMR or dMMR) or metastatic dMMR endometrial cancer
- A scan shows at least one measurable tumor spot you can follow (by specific size rules)
- You already had at least one treatment for metastatic colorectal cancer, or you refused comfort/“palliative” chemotherapy (with proof in your record)
- You are expected to live more than 3 months
- Your blood counts and organ tests (liver/kidney, etc.) are within acceptable ranges
- You can give written consent (and you’re at least 18), and you can provide tumor tissue samples before and after treatment when possible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the immunotherapy drug tislelizumab for people with a specific type of colorectal or rectal cancer called dMMR. It aims to see if this treatment can shrink tumors or improve outcomes in patients who haven't had many other treatments.
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
This trial tests new immunotherapy combinations given before surgery for cancers that have certain genetic features (dMMR or pMMR). It aims to see if these drugs can shrink tumors and improve outcomes for patients with various cancer types, including those for which standard neoadjuvant therapy is not an option.
This trial tests a new two-drug combination (LB-100 plus atezolizumab) for people with metastatic colorectal cancer that hasn't responded to standard treatment. The goal is to see if the combination can help shrink or slow the cancer.
This trial tests a combination of two medicines (camrelizumab and anlotinib) for endometrial cancer that has spread back or continued and has specific tumor gene changes called MMRd. It may help shrink tumors or control the disease by activating the immune system and blocking cancer growth signals.
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.